TG Therapeutics (TGTX) Earnings Announcement Set for November 4

TG Therapeutics (NASDAQ:TGTX) is scheduled to announce its quarterly earnings before the market opens on Monday, November 4th. Analysts are anticipating the company to report earnings of $0.04 per share for the quarter.

The last time TG Therapeutics released its earnings data was on Tuesday, August 6th. During that quarter, the biopharmaceutical firm posted earnings of $0.04 per share, exceeding expectations, which had predicted a loss of ($0.04) per share. The company reported a strong return on equity of 57.73% alongside a net margin of 27.60%. Revenue for the quarter came in at $73.47 million, significantly higher than the analyst forecast of $65.92 million. This marked a remarkable increase of 357.0% in revenue compared to the same quarter last year when the company reported a loss of ($0.34) earnings per share. Looking ahead, analysts estimate that TG Therapeutics will post $0 EPS for the current fiscal year while projecting $1 EPS for the upcoming fiscal year.

TG Therapeutics Stock Performance

As of Friday, shares of TGTX opened at $26.90, with a market capitalization of $4.16 billion. The company's price-to-earnings ratio stands at 44.10, with a beta of 2.21. TG Therapeutics carries a debt-to-equity ratio of 0.58, showcasing a current ratio of 3.58 and a quick ratio of 2.83. The stock has seen a low of $9.81 and a high of $26.99 over the past year. Currently, the 50-day moving average is at $23.51 while the 200-day moving average is $20.01.

Analysts' Perspectives on TG Therapeutics

Research analysts have expressed various insights on TG Therapeutics stock. The Goldman Sachs Group adjusted their price target from $18.00 to $20.00, rating the stock as "neutral" in a report released on August 7th. In a new report, TD Cowen initiated coverage on TG Therapeutics and assigned a "buy" rating with a target price of $50.00. Another firm, HC Wainwright, reaffirmed a "buy" rating in a report on September 18th, placing a price target at $49.00. Moreover, B. Riley increased their price objective from $29.00 to $34.00, also rating it a "buy." At this point, two analysts have given the stock a hold rating, while five analysts have issued a buy rating. According to MarketBeat data, TG Therapeutics currently has an average rating classified as "Moderate Buy" along with an average price target of $36.33.

Overview of TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical company operating at a commercial stage, focusing on developing and marketing innovative treatments for B-cell mediated diseases both in the United States and internationally. The company is known for its product BRIUMVI, an anti-CD20 monoclonal antibody aimed at treating adult patients who suffer from relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

earnings, stocks, biopharmaceutical